Literature DB >> 24082068

Surface charge of Streptococcus pneumoniae predicts serotype distribution.

Yuan Li1, Daniel M Weinberger, Claudette M Thompson, Krzysztof Trzciński, Marc Lipsitch.   

Abstract

Streptococcus pneumoniae (pneumococcus) frequently colonizes the human nasopharynx and is an important cause of pneumonia, meningitis, sinusitis, and otitis media. The outer cell surface of pneumococcus may assume various degrees of negative charge depending on the polysaccharide capsule, of which more than 90 serotypes have been identified. The negative charge of capsular polysaccharides has been proposed to electrostatically repel pneumococci from phagocytic cells, and avoidance of phagocytosis correlates with higher carriage prevalence. We hypothesized that the surface charge of pneumococcus contributes to its success in nasopharyngeal carriage by modulating resistance to phagocyte-mediated killing. Here, we measured the surface charge (zeta potential) of laboratory-constructed strains that share a genetic background but differ in serotype and of clinical strains that differ in serotype and genetic background. A more negative surface charge correlated with higher resistance to nonopsonic killing by human neutrophils in vitro. In addition, a more negative zeta potential was associated with higher carriage prevalence in human populations before and after the widespread use of the pneumococcal conjugate vaccine PCV7. We also confirmed that capsule is the major determinant of net surface charge in clinical isolates with diverse backgrounds. We noted that exceptions exist to the idea that a higher magnitude of negative charge predicts higher prevalence. The results indicated that zeta potential is strongly influenced by pneumococcal capsule type but is unlikely to be the only important mechanism by which capsule interacts with host.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24082068      PMCID: PMC3837974          DOI: 10.1128/IAI.00724-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

Review 1.  Status of methods for assessing bacterial cell surface charge properties based on zeta potential measurements.

Authors:  W W Wilson; M M Wade; S C Holman; F R Champlin
Journal:  J Microbiol Methods       Date:  2001-01       Impact factor: 2.363

2.  Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland.

Authors:  William P Hanage; Tarja H Kaijalainen; Ritva K Syrjänen; Kari Auranen; Maija Leinonen; P Helena Mäkelä; Brian G Spratt
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

4.  Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

Authors:  Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

5.  Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.

Authors:  Aaron L Nelson; Aoife M Roche; Jane M Gould; Kannie Chim; Adam J Ratner; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

6.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

7.  Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.

Authors:  Rebecca A Gladstone; Johanna M Jefferies; Saul N Faust; Stuart C Clarke
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

Review 8.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

9.  Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b.

Authors:  Catherine Hyams; Krzysztof Trzcinski; Emilie Camberlein; Daniel M Weinberger; Suneeta Chimalapati; Mahdad Noursadeghi; Marc Lipsitch; Jeremy S Brown
Journal:  Infect Immun       Date:  2012-11-12       Impact factor: 3.441

10.  Pneumococcal capsular polysaccharide structure predicts serotype prevalence.

Authors:  Daniel M Weinberger; Krzysztof Trzciński; Ying-Jie Lu; Debby Bogaert; Aaron Brandes; James Galagan; Porter W Anderson; Richard Malley; Marc Lipsitch
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

View more
  31 in total

1.  Improving vaccines against Streptococcus pneumoniae using synthetic glycans.

Authors:  Paulina Kaplonek; Naeem Khan; Katrin Reppe; Benjamin Schumann; Madhu Emmadi; Marilda P Lisboa; Fei-Fei Xu; Adam D J Calow; Sharavathi G Parameswarappa; Martin Witzenrath; Claney L Pereira; Peter H Seeberger
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-07       Impact factor: 11.205

2.  Pneumococcal Phenotype and Interaction with Nontypeable Haemophilus influenzae as Determinants of Otitis Media Progression.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Paula A Tähtinen; Ron Dagan
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

3.  Glycan Microarrays Containing Synthetic Streptococcus pneumoniae CPS Fragments and Their Application to Vaccine Development.

Authors:  Paulina Kaplonek; Peter H Seeberger
Journal:  Methods Mol Biol       Date:  2022

4.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

Review 5.  Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection.

Authors:  A P Hakansson; C J Orihuela; D Bogaert
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

6.  The blp Locus of Streptococcus pneumoniae Plays a Limited Role in the Selection of Strains That Can Cocolonize the Human Nasopharynx.

Authors:  Carina Valente; Suzanne Dawid; Francisco R Pinto; Jason Hinds; Alexandra S Simões; Katherine A Gould; Luís A Mendes; Hermínia de Lencastre; Raquel Sá-Leão
Journal:  Appl Environ Microbiol       Date:  2016-08-15       Impact factor: 4.792

7.  Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Daniel M Weinberger; Marc Lipsitch; Ron Dagan
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

8.  Risk factors for death from invasive pneumococcal disease, Europe, 2010.

Authors:  Adoración Navarro-Torné; Joana Gomes Dias; Frantiska Hruba; Pier Luigi Lopalco; Lucia Pastore-Celentano; Andrew J Amato Gauci
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

9.  Emerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitro.

Authors:  Mirian Domenech; Diana Damián; Carmen Ardanuy; Josefina Liñares; Asunción Fenoll; Ernesto García
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

10.  Identification of pneumococcal colonization determinants in the stringent response pathway facilitated by genomic diversity.

Authors:  Yuan Li; Nicholas J Croucher; Claudette M Thompson; Krzysztof Trzciński; William P Hanage; Marc Lipsitch
Journal:  BMC Genomics       Date:  2015-05-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.